---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-26-000782"
form_type: "8-K"
ticker: "SRTS"
cik: "0001494891"
company_name: "Sensus Healthcare, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:36:06.390291+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sensus Healthcare Q1 revenue drops to $3.4M; cash $18.3M, no debt

## Summary
- Revenue of $3.4M, down 59% vs $8.3M in Q1 2025; no sales to historically largest customer (15 units in prior year).
- Shipped 14 SRT systems (10 direct, 4 placements) vs 30 in prior year; excluding largest customer sales, revenue up from $2.7M.
- Gross margin fell to 29.2% from 52.2% due to product mix and Fair Deal placements; adjusted EBITDA -$4.2M vs -$2.5M.
- New CPT codes for SRT effective Jan 1, 2026 drove higher inquiry levels and pipeline activity.
- Launched Sensus Healthcare Financial Services and Sensus Link; Fair Deal treatment volumes up 8% YoY.

## SEC filing metadata
- accession: 0001753926-26-000782
- form_type: 8-K
- ticker: SRTS
- cik: 0001494891
- company_name: Sensus Healthcare, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1494891/000175392626000782/0001753926-26-000782-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1494891/000175392626000782/g085707_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-26-000782
- JSON: https://secwatch.observer/filing/0001753926-26-000782.json
- Plain text: https://secwatch.observer/filing/0001753926-26-000782.txt

## Source-grounded claims
- claim_id: 5d0aba03ba5239a681fdc0be3e255bf0849ae826
  claim: Sensus Healthcare, Inc. reported the three months ended March 31, 2026 results: revenue $3.4 million.
  evidence_excerpt: and non-oncological skin conditions, today announced financial results and business highlights for the three months ended March 31, 2026. Highlights included: ● Revenue of $3.4 million compared to $8.3 million for the three months ended March 31, 2025. o Excluding sales to the Company’s historically largest customer, revenue increased from $2.7 million in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1494891/000175392626000782/0001753926-26-000782-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.